West Pharmaceutical Services, Inc. (WST)
After hours:
Chart Events
Performance Outlook
| Previous Close | 341.19 |
| Open | 340.59 |
| Bid | 330.74 x 1100 |
| Ask | 344.80 x 1800 |
| Day's Range | 338.30 - 342.27 |
| 52 Week Range | 224.15 - 415.73 |
| Volume | |
| Avg. Volume | 380,482 |
| Market Cap | 25.322B |
| Beta (5Y Monthly) | 1.07 |
| PE Ratio (TTM) | 46.06 |
| EPS (TTM) | 7.43 |
| Earnings Date | Feb 14, 2024 - Feb 19, 2024 |
| Forward Dividend & Yield | 0.80 (0.23%) |
| Ex-Dividend Date | Jan 30, 2024 |
| 1y Target Est | 390.43 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for WST
Related Research
- West Pharmaceutical Services, IWST: Lowering target price to $361.00WEST PHARMACEUTICAL SERVICES has an Investment Rating of HOLD; a target price of $361.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat3 days agoArgus Research
PR NewswireWest Announces First-Quarter 2024 Dividend
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a first-quarter 2024 dividend of $0.20 per share. The dividend will be paid on February 7, 2024, to shareholders of record as of January 31, 2024.
ZacksWest Pharmaceutical's (WST) New Launch to Expand Portfolio
West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.
PR NewswireWest Receives FDA 510(k) Clearance for Vial2Bag Advanced® 13mm Admixture Device
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration systems, today announced FDA 510(k) clearance and launch of its Vial2Bag Advanced® 13mm admixture device.
